XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:        
Revenue from collaborative arrangements and other contracts $ 9,154,133 $ 291,698 $ 10,137,602 $ 935,643
Operating expenses:        
Research and development 33,087,130 47,088,669 145,530,626 156,941,505
General and administrative 11,824,047 13,156,183 76,234,341 39,703,718
Total operating expenses 44,911,177 60,244,852 221,764,967 196,645,223
Loss from operations (35,757,044) (59,953,154) (211,627,365) (195,709,580)
Other income (expense):        
Interest income 1,365,759 766,271 2,893,240 2,463,618
Interest expense (313,488) (476,374) (940,464) (1,456,134)
Loss on investment in affiliated entities (305,061) (21,999) (1,776,804) (573,656)
Net unrealized loss on available-for-sale equity securities (1,833,284) (455,299) (10,641,026) (1,166,764)
Other (expense) income, net (940,778) (28,486) (1,097,294) 165,773
Net loss before share in net loss of Geneos (37,783,896) (60,169,041) (223,189,713) (196,276,743)
Share in net loss of Geneos 0 0 (2,165,213) (434,387)
Net loss $ (37,783,896) $ (60,169,041) $ (225,354,926) $ (196,711,130)
Net loss per share        
Basic (in dollars per share) $ (0.15) $ (0.29) $ (0.96) $ (0.95)
Diluted (in dollars per share) $ (0.15) $ (0.29) $ (0.96) $ (0.95)
Weighted average number of common shares outstanding        
Basic (in shares) 249,351,023 210,304,836 234,634,724 207,455,684
Diluted (in shares) 249,351,023 210,304,836 234,634,724 207,455,684